Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 129

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 129
---
, our Chief Commercial Officer in 2023, and our Chief Corporate Development and Strategy Officer in March 2025, our Board of Directors granted each of them equity awards in the form of stock options, RSUs and PSUs, which awards were made outside our equity incentive plans as inducements material to their respective entry into employment with us in accordance with Nasdaq Listing Rule 5635(c)(4).As of June 30, 2025, the maximum number of shares reserved under the 2013 Plan, the 2023 Plan and the inducement grants described above was 12,661,855, and we had 3,664,151 shares available for future issuance under the 2023 Plan.Stock optionsThe following table presents stock option activity for the six months ended June 30, 2025:Number ofStock OptionsWeighted-AverageExercise PriceOutstanding at December 31, 20245,834,256 $43.48 Granted885,023 33.40 Exercised(3,783)29.10 Cancelled/Forfeited(80,385)45.29 Expired(210,536)106.49 Outstanding at June 30, 20256,424,575 $40.01 Exercisable at June 30, 20254,243,623 $44.21 Vested and expected to vest at June 30, 20256,424,575 $40.01 At June 30, 2025, there was approximately $35.8 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.57 years.Restricted stock unitsThe following table presents RSU activity for the six months ended June 30, 2025:Number ofStock UnitsWeighted-AverageGrant Date Fair ValueUnvested shares at December 31, 20241,818,563 $30.31 Granted1,114,325 33.16 Vested(743,358)30.06 Forfeited(93,407)30.56 Unvested shares at June 30, 20252,096,123 $31.90 As of June 30, 2025, there was approximately $53.6 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a